Kelly Brown, MD
Family Medicine · Cincinnati, OHNPI 1952505901
Payments from drug & device makers
Across 249 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$925
- Novo Nordisk$447
- Pfizer$398
- Abbott$273
- Lilly USA, LLC$259
- Johnson & Johnson$187
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,073100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $925 |
| Novo Nordisk | 28 | $447 |
| Pfizer | 25 | $398 |
| Abbott | 14 | $273 |
| Lilly USA, LLC | 17 | $259 |
| Johnson & Johnson | 14 | $187 |
| AstraZeneca | 13 | $179 |
| GSK | 11 | $179 |
| Otsuka America Pharmaceutical, Inc. | 4 | $174 |
| Boehringer Ingelheim | 10 | $167 |
| Amgen | 6 | $111 |
| Bayer | 4 | $74 |
| Exact Sciences | 3 | $66 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Merck | 3 | $50 |
| Dexcom, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,085 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 69 | $88,942 |
| OzempicSemaglutide | 64 | $69,663 |
| TrulicityDulaglutide | 52 | $57,319 |
| XareltoRivaroxaban | 38 | $36,376 |
| EliquisApixaban | 37 | $34,990 |
| MounjaroTirzepatide | 26 | $34,798 |
| JanuviaSitagliptin Phosphate | 26 | $23,885 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $21,191 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,762 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $8,568 |
| InvokanaCanagliflozin | 12 | $6,991 |
| MyrbetriqMirabegron | 11 | $6,378 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $4,177 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $3,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $259 | $92,11878 claims |
| Boehringer IngelheimJardiance | $167 | $88,94269 claims |
| Novo NordiskOzempic | $447 | $69,66364 claims |
| Johnson & JohnsonXarelto, Invokana | $187 | $43,36850 claims |
| PfizerEliquis, Paxlovid | $398 | $36,41958 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $179 | $29,75928 claims |
| MerckJanuvia | $50 | $23,88526 claims |
| AstraZenecaSymbicort | $179 | $5,43915 claims |
| AbbVieSynthroid | $925 | $1,06023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.